Role of Insulin Resistance in MAFLD
Open accessThe DOI matches its Crossref record; 195 of the 195 references it cites were found in a registry or an index.
Abstract
Many studies have reported that metabolic dysfunction is closely involved in the complex mechanism underlying the development of non-alcoholic fatty liver disease (NAFLD), which has prompted a movement to consider renaming NAFLD as metabolic dysfunction-associated fatty liver disease (MAFLD). Metabolic dysfunction in this context encompasses obesity, type 2 diabetes mellitus, hypertension, dyslipidemia, and metabolic syndrome, with insulin resistance as the common underlying pathophysiology. Imbalance between energy intake and expenditure results in insulin resistance in various tissues and alteration of the gut microbiota, resulting in fat accumulation in the liver. The role of genetics has also been revealed in hepatic fat accumulation and fibrosis. In the process of fat accumulation in the liver, intracellular damage as well as hepatic insulin resistance further potentiates inflammation, fibrosis, and carcinogenesis. Increased lipogenic substrate supply from other tissues, hepatic zonation of Irs1, and other factors, including ER stress, play crucial roles in increased hepatic de novo lipogenesis in MAFLD with hepatic insulin resistance. Herein, we provide an overview of the factors contributing to and the role of systemic and local insulin resistance in the development and progression of MAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Given that insulin resistance (IR) is widely recognized as the key underlying mechanism of metabolic syndrome, it is reasonable to consider IR as a central factor in the pathogenesis of MASLD, which can be viewed as the hepatic manifestation of metabolic syndrome [2,9-12].”
The cited source says what the claim attributes to it.
In the citing paper
“ChREBP, which is activated by carbohydrate uptake [9,34,78,83].”
The cited source says what the claim attributes to it.
In the citing paper
“Among the core insulin signaling mediators—including INSR, IRS1, IRS2, AKT1, and AKT2—IRS1 shows marked zonal expression, with approximately 2-fold higher levels in PV compared to PP regions [9,20].”
In the citing paper
“Many studies have shown that insulin- resistant conditions are accompanied by a substantial increase in MTP and apolipoprotein C3 (ApoCIII) expression and the production of hepatic VLDL-ApoB and VLDL-TG [2, 9,108,111].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
MORA, A., LIPINA, C., TRONCHE, F., SUTHERLAND, C., & ALESSI, D. R. (2005) · Biochemical Journal · doi:10.1042/bj20041782 · Cited by 92
RetractedSarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance
Hotamisligil, G. S., Shargill, N. S., & Spiegelman, B. M. (1993) · Science · doi:10.1126/science.7678183 · Cited by 7,518
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Metabolic Endotoxemia Initiates Obesity and Insulin Resistance
Cani, P. D., Amar, J., Iglesias, M. A., Poggi, M., Knauf, C., Bastelica, D., Neyrinck, A. M., Fava, F., Tuohy, K. M., Chabo, C., et al. (2007) · Diabetes · doi:10.2337/db06-1491 · Cited by 6,638
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · cited 1×
“The global prevalence of NAFLD is estimated at 24%; the highest rates are reported from South America and the Middle East, followed by Asia, the USA, and Europe [3].”
BackgroundSREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afz046 · Cited by 3,803
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 1×
“In NAFLD and obes patients, the TG composition of the liver is reported to be 59% from NEFA, 26% from DNL, and 15% from the diet, suggesting that DNL is elevated in the fasting state in NAFLD and that the NEFA pool is the primary contributor to hepatic TG in NAFLD [42].”
BackgroundGenetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548 · cited 2×
“mechanism involved in the progression from NAFLD to NASH/HCC, inflammatory mediators derived from various tissues could play a central role in the cascade of inflammation, fibrosis, and finally tumor development [7], and metabolic dysfunction is considered to be closely associated with these kinds of inflammatory chan…”
BackgroundDiet–microbiota interactions as moderators of human metabolism
Sonnenburg, J. L., & Bäckhed, F. (2016) · Nature · doi:10.1038/nature18846 · Cited by 2,257
Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes
DeFronzo, R. A., & Tripathy, D. (2009) · Diabetes Care · doi:10.2337/dc09-s302 · Cited by 2,102 · cited 14×
“Humans with congenital generalized lipodystrophy develop extreme insulin resistance and its complications, such as T2DM, hyperlipidemia, and fatty liver [66].”
BackgroundInfluentialAdipose tissue remodeling and obesity
Sun, K., Kusminski, C. M., & Scherer, P. E. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45887 · Cited by 1,941
Yuan, M., Konstantopoulos, N., Lee, J., Hansen, L., Li, Z.-W., Karin, M., & Shoelson, S. E. (2001) · Science · doi:10.1126/science.1061620 · Cited by 1,884 · cited 1×
“These effects were mediated by the activated IKKβ-NF-κB pathway [73].”
BackgroundZhu, L., Baker, S. S., Gill, C., Liu, W., Alkhouri, R., Baker, R. D., & Gill, S. R. (2013) · Hepatology · doi:10.1002/hep.26093 · Cited by 1,708
Boursier, J., Mueller, O., Barret, M., Machado, M., Fizanne, L., Araujo‐Perez, F., Guy, C. D., Seed, P. C., Rawls, J. F., David, L. A., et al. (2016) · Hepatology · doi:10.1002/hep.28356 · Cited by 1,483
Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease
Ipsen, D. H., Lykkesfeldt, J., & Tveden-Nyborg, P. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2860-6 · Cited by 1,471 · cited 1×
“Hepatic steatosis, secondary to compromised TG export, is common in patients with genetic defects in the ApoB or MTP gene [59].”
BackgroundIncreased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease
Miele, L., Valenza, V., La Torre, G., Montalto, M., Cammarota, G., Ricci, R., Mascianà, R., Forgione, A., Gabrieli, M. L., Perotti, G., et al. (2009) · Hepatology · doi:10.1002/hep.22848 · Cited by 1,434
Visceral fat adipokine secretion is associated with systemic inflammation in obese humans
Fontana, L., Eagon, J. C., Trujillo, M. E., Scherer, P. E., & Klein, S. (2007) · Diabetes · doi:10.2337/db06-1656 · Cited by 1,417 · cited 1×
“Enhanced secretion of interleukin-6 (IL-6) from the visceral adipose tissue has been observed in obese individuals [76].”
BackgroundYamauchi, T., Nio, Y., Maki, T., Kobayashi, M., Takazawa, T., Iwabu, M., Okada-Iwabu, M., Kawamoto, S., Kubota, N., Kubota, T., et al. (2007) · Nature Medicine · doi:10.1038/nm1557 · Cited by 1,396 · cited 1×
“In the liver, AdipoR1 is involved in the activation of AMP-activated kinase (AMPK), and AdipoR2 is involved in the activation of PPARα, both of which lead to increased insulin sensitivity [86].”
BackgroundSelf-citationHuang, S., & Czech, M. P. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.03.006 · Cited by 1,385
Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease
Samuel, V. T., Liu, Z.-X., Qu, X., Elder, B. D., Bilz, S., Befroy, D., Romanelli, A. J., & Shulman, G. I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313478200 · Cited by 1,322
Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317797 · Cited by 1,298
Michael, M. D., Kulkarni, R. N., Postic, C., Previs, S. F., Shulman, G. I., Magnuson, M. A., & Kahn, C. R. (2000) · Molecular Cell · doi:10.1016/s1097-2765(05)00015-8 · Cited by 1,296
Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17797 · Cited by 1,296
Bedogni, G., Miglioli, L., Masutti, F., Tiribelli, C., Marchesini, G., & Bellentani, S. (2005) · Hepatology · doi:10.1002/hep.20734 · Cited by 1,263
Kozlitina, J., Smagris, E., Stender, S., Nordestgaard, B. G., Zhou, H. H., Tybjærg-Hansen, A., Vogt, T. F., Hobbs, H. H., & Cohen, J. C. (2014) · Nature Genetics · doi:10.1038/ng.2901 · Cited by 1,234 · cited 2×
“Tm6sf2 in mice increased the liver TG content and decreased VLDL secretion [32], sug-”
BackgroundBrüning, J. C., Michael, M. D., Winnay, J. N., Hayashi, T., Hörsch, D., Accili, D., Goodyear, L. J., & Kahn, C. R. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80155-0 · Cited by 1,182
Endoplasmic reticulum stress in liver disease
Malhi, H., & Kaufman, R. J. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.11.005 · Cited by 1,173
Lambert, J. E., Ramos–Roman, M. A., Browning, J. D., & Parks, E. J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.11.049 · Cited by 1,069 · cited 1×
“In an experiment conducted with isotopes, a threefold increase of DNL and higher nocturnal plasma levels of FFAs were observed in patients with NAFLD [41].”
BackgroundGut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders
Aron-Wisnewsky, J., Vigliotti, C., Witjes, J., Le, P., Holleboom, A. G., Verheij, J., Nieuwdorp, M., & Clément, K. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0269-9 · Cited by 1,063
Koliaki, C., Szendroedi, J., Kaul, K., Jelenik, T., Nowotny, P., Jankowiak, F., Herder, C., Carstensen, M., Krausch, M., Knoefel, W. T., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.04.004 · Cited by 1,032 · cited 1×
“Elevated hepatic insulin resistance, mitochondrial uncoupling, and leaking activity might result in augmented hepatic oxidative stress and inflammatory response [48].”
BackgroundThe role of the gut microbiota in NAFLD
Leung, C., Rivera, L., Furness, J. B., & Angus, P. W. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.85 · Cited by 1,020
Tilg, H., Moschen, A. R., & Roden, M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.147 · Cited by 1,002
Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity
Fabbrini, E., Magkos, F., Mohammed, B. S., Pietka, T., Abumrad, N. A., Patterson, B. W., Okunade, A., & Klein, S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904944106 · Cited by 972
Genetics and epigenetics of NAFLD and NASH: Clinical impact
Eslam, M., Valenti, L., & Romeo, S. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.003 · Cited by 971
Selective versus Total Insulin Resistance: A Pathogenic Paradox
Brown, M. S., & Goldstein, J. L. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.12.009 · Cited by 965
Splanchnic lipolysis in human obesity
Nielsen, S., Guo, Z., Johnson, C. M., Hensrud, D. D., & Jensen, M. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21047 · Cited by 933
Cusi, K. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.003 · Cited by 911
SHIMOMURA, I. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00009-5 · Cited by 855
PPARs in Obesity-Induced T2DM, Dyslipidaemia and NAFLD
Gross, B., Pawlak, M., Lefebvre, P., & Staels, B. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.135 · Cited by 778
Regulation of mTORC1 by amino acids
Bar-Peled, L., & Sabatini, D. M. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.03.003 · Cited by 773
Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease
Smith, G. I., Shankaran, M., Yoshino, M., Schweitzer, G. G., Chondronikola, M., Beals, J. W., Okunade, A. L., Patterson, B. W., Nyangau, E., Field, T., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134165 · Cited by 771
The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome
Petersen, K. F., Dufour, S., Savage, D. B., Bilz, S., Solomon, G., Yonemitsu, S., Cline, G. W., Befroy, D., Zemany, L., Kahn, B. B., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705408104 · Cited by 759
Intestinal microbiota in patients with nonalcoholic fatty liver disease
Mouzaki, M., Comelli, E. M., Arendt, B. M., Bonengel, J., Fung, S. K., Fischer, S. E., McGilvray, I. D., & Allard, J. P. (2013) · Hepatology · doi:10.1002/hep.26319 · Cited by 749
Li, S., Brown, M. S., & Goldstein, J. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914798107 · Cited by 733
Ballestri, S., Zona, S., Targher, G., Romagnoli, D., Baldelli, E., Nascimbeni, F., Roverato, A., Guaraldi, G., & Lonardo, A. (2016) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13264 · Cited by 717
Shimomura, I., Bashmakov, Y., & Horton, J. D. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.42.30028 · Cited by 708
Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas
Horie, Y., Suzuki, A., Kataoka, E., Sasaki, T., Hamada, K., Sasaki, J., Mizuno, K., Hasegawa, G., Kishimoto, H., Iizuka, M., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420513 · Cited by 698
Crespo, J., Cayón, A., Fernández-Gil, P., Hernández-Guerra, M., Mayorga, M., Domínguez-Díez, A., Fernández-Escalante, J. C., & Pons-Romero, F. (2001) · Hepatology · doi:10.1053/jhep.2001.29628 · Cited by 693
Mancina, R. M., Dongiovanni, P., Petta, S., Pingitore, P., Meroni, M., Rametta, R., Borén, J., Montalcini, T., Pujia, A., Wiklund, O., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.032 · Cited by 676
Sunny, N. E., Parks, E. J., Browning, J. D., & Burgess, S. C. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.11.004 · Cited by 672
Yecies, J. L., Zhang, H. H., Menon, S., Liu, S., Yecies, D., Lipovsky, A. I., Gorgun, C., Kwiatkowski, D. J., Hotamisligil, G. S., Lee, C.-H., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.06.002 · Cited by 657
The gut microbiome and metabolic syndrome
Dabke, K., Hendrick, G., & Devkota, S. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129194 · Cited by 654
Parlesak, A., Schäfer, C., Schütz, T., Bode, J. C., & Bode, C. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80242-1 · Cited by 647
Fabbrini, E., Mohammed, B. S., Magkos, F., Korenblat, K. M., Patterson, B. W., & Klein, S. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.11.038 · Cited by 631
Rui, L., Aguirre, V., Kim, J. K., Shulman, G. I., Lee, A., Corbould, A., Dunaif, A., & White, M. F. (2001) · Journal of Clinical Investigation · doi:10.1172/jci10934 · Cited by 607
A Stress Signaling Pathway in Adipose Tissue Regulates Hepatic Insulin Resistance
Sabio, G., Das, M., Mora, A., Zhang, Z., Jun, J. Y., Ko, H. J., Barrett, T., Kim, J. K., & Davis, R. J. (2008) · Science · doi:10.1126/science.1160794 · Cited by 604
Activation and Dysregulation of the Unfolded Protein Response in Nonalcoholic Fatty Liver Disease
Puri, P., Mirshahi, F., Cheung, O., Natarajan, R., Maher, J. W., Kellum, J. M., & Sanyal, A. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.10.039 · Cited by 597
Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease
Kumashiro, N., Erion, D. M., Zhang, D., Kahn, M., Beddow, S. A., Chu, X., Still, C. D., Gerhard, G. S., Han, X., Dziura, J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113359108 · Cited by 585
Buch, S., Stickel, F., Trépo, E., Way, M., Herrmann, A., Nischalke, H. D., Brosch, M., Rosendahl, J., Berg, T., Ridinger, M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3417 · Cited by 565 · cited 2×
“hol-related cirrhosis [34], have also been shown to be associated with the development”
BackgroundLiu, Y.-L., Patman, G. L., Leathart, J. B. S., Piguet, A.-C., Burt, A. D., Dufour, J.-F., Day, C. P., Daly, A. K., Reeves, H. L., & Anstee, Q. M. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.02.030 · Cited by 549 · cited 4×
“Although NASH with cirrhosis is thought to predispose to hepatocellular carcinoma (HCC), hepatocarcinogenesis has also come to be increasingly recognized in NASH patients without cirrhosis [6].”
BackgroundInfluentialA high-fat diet is associated with endotoxemia that originates from the gut
Pendyala, S., Walker, J. M., & Holt, P. R. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.01.034 · Cited by 546
Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease
Khan, R. S., Bril, F., Cusi, K., & Newsome, P. N. (2019) · Hepatology · doi:10.1002/hep.30429 · Cited by 542
PPARs as Metabolic Regulators in the Liver: Lessons from Liver-Specific PPAR-Null Mice
Wang, Y., Nakajima, T., Gonzalez, F. J., & Tanaka, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062061 · Cited by 540
Dongiovanni, P., Petta, S., Maglio, C., Fracanzani, A. L., Pipitone, R., Mozzi, E., Motta, B. M., Kaminska, D., Rametta, R., Grimaudo, S., et al. (2015) · Hepatology · doi:10.1002/hep.27490 · Cited by 533 · cited 1×
“While subjects with the TM6SF2-E167K variant are more susceptible to progressive NASH, the incidence of cardiovascular events in these patients is reported to be lower, because of the lower levels of circulating lipids [33].”
BackgroundBoden, G., She, P., Mozzoli, M., Cheung, P., Gumireddy, K., Reddy, P., Xiang, X., Luo, Z., & Ruderman, N. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3458 · Cited by 528
Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?
Rada, P., González-Rodríguez, Á., García-Monzón, C., & Valverde, Á. M. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-03003-w · Cited by 518
Increased Hepatic CD36 Expression Contributes to Dyslipidemia Associated With Diet-Induced Obesity
Koonen, D. P. Y., Jacobs, R. L., Febbraio, M., Young, M. E., Soltys, C.-L. M., Ong, H., Vance, D. E., & Dyck, J. R. B. (2007) · Diabetes · doi:10.2337/db07-0907 · Cited by 511
Obesity, inflammation, and liver cancer
Sun, B., & Karin, M. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.09.020 · Cited by 496
Biddinger, S. B., Hernandez-Ono, A., Rask-Madsen, C., Haas, J. T., Alemán, J. O., Suzuki, R., Scapa, E. F., Agarwal, C., Carey, M. C., Stephanopoulos, G., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.11.013 · Cited by 469
Dong, X. C., Copps, K. D., Guo, S., Li, Y., Kollipara, R., DePinho, R. A., & White, M. F. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.06.006 · Cited by 463
Wilson, C. G., Tran, J. L., Erion, D. M., Vera, N. B., Febbraio, M., & Weiss, E. J. (2016) · Endocrinology · doi:10.1210/en.2015-1866 · Cited by 463
Miquilena-Colina, M. E., Lima-Cabello, E., Sánchez-Campos, S., García-Mediavilla, M. V., Fernández-Bermejo, M., Lozano-Rodríguez, T., Vargas-Castrillón, J., Buqué, X., Ochoa, B., Aspichueta, P., et al. (2011) · Gut · doi:10.1136/gut.2010.222844 · Cited by 451
Insulin signaling in health and disease
Saltiel, A. R. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142241 · Cited by 446
Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis
Koo, B. K., Kim, D., Joo, S. K., Kim, J. H., Chang, M. S., Kim, B. G., Lee, K. L., & Kim, W. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.08.019 · Cited by 440
Stiles, B., Wang, Y., Stahl, A., Bassilian, S., Lee, W. P., Kim, Y.-J., Sherwin, R., Devaskar, S., Lesche, R., Magnuson, M. A., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308617100 · Cited by 436
Zhang, H. H., Halbleib, M., Ahmad, F., Manganiello, V. C., & Greenberg, A. S. (2002) · Diabetes · doi:10.2337/diabetes.51.10.2929 · Cited by 434
Liver-Specific Inhibition of ChREBP Improves Hepatic Steatosis and Insulin Resistance in ob/ob Mice
Dentin, R., Benhamed, F., Hainault, I., Fauveau, V., Foufelle, F., Dyck, J. R. B., Girard, J., & Postic, C. (2006) · Diabetes · doi:10.2337/db06-0200 · Cited by 433
Gene expression in human NAFLD
Greco, D., Kotronen, A., Westerbacka, J., Puig, O., Arkkila, P., Kiviluoto, T., Laitinen, S., Kolak, M., Fisher, R. M., Hamsten, A., et al. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00074.2008 · Cited by 427 · cited 1×
“The expression of CD36 was found to be upregulated in patients with high hepatic fat content [54].”
BackgroundAdiponectin Receptor as a Key Player in Healthy Longevity and Obesity-Related Diseases
Yamauchi, T., & Kadowaki, T. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.01.001 · Cited by 415
Self-citationBenhamed, F., Denechaud, P.-D., Lemoine, M., Robichon, C., Moldes, M., Bertrand-Michel, J., Ratziu, V., Serfaty, L., Housset, C., Capeau, J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci41636 · Cited by 408
Bugianesi, E., Pagotto, U., Manini, R., Vanni, E., Gastaldelli, A., de Iasio, R., Gentilcore, E., Natale, S., Cassader, M., Rizzetto, M., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2240 · Cited by 408
Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver
Satapati, S., Kucejova, B., Duarte, J. A. G., Fletcher, J. A., Reynolds, L., Sunny, N. E., He, T., Nair, L. A., Livingston, K., Fu, X., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82204 · Cited by 399
Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus
Targher, G., Lonardo, A., & Byrne, C. D. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.173 · Cited by 397
Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1
Lu, M., Wan, M., Leavens, K. F., Chu, Q., Monks, B. R., Fernandez, S., Ahima, R. S., Ueki, K., Kahn, C. R., & Birnbaum, M. J. (2012) · Nature Medicine · doi:10.1038/nm.2686 · Cited by 395
Update on NAFLD genetics: From new variants to the clinic
Trépo, E., & Valenti, L. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.02.020 · Cited by 393 · cited 2×
“Many genome-wide association studies have identified novel loci associated with disease severity phenotypes of NAFLD and NASH [24,25] (Figure 1).”
BackgroundElevated endotoxin levels in non-alcoholic fatty liver disease
Harte, A. L., da Silva, N. F., Creely, S. J., McGee, K. C., Billyard, T., Youssef-Elabd, E. M., Tripathi, G., Ashour, E., Abdalla, M. S., Sharada, H. M., et al. (2010) · Journal of Inflammation · doi:10.1186/1476-9255-7-15 · Cited by 390
Hong, H. C., Hwang, S. Y., Choi, H. Y., Yoo, H. J., Seo, J. A., Kim, S. G., Kim, N. H., Baik, S. H., Choi, D. S., & Choi, K. M. (2014) · Hepatology · doi:10.1002/hep.26716 · Cited by 385
Ikejima, K., Takei, Y., Honda, H., Hirose, M., Yoshikawa, M., Zhang, Y.-J., Lang, T., Fukuda, T., Yamashina, S., Kitamura, T., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.32995 · Cited by 385
Roles of diacylglycerols and ceramides in hepatic insulin resistance
Petersen, M. C., & Shulman, G. I. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.04.004 · Cited by 373
Mitochondrial dysfunction in metabolic syndrome
Prasun, P. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165838 · Cited by 364
Keshavarzian, A., Farhadi, A., Forsyth, C. B., Rangan, J., Jakate, S., Shaikh, M., Banan, A., & Fields, J. Z. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.10.028 · Cited by 359
Cope, K., Risby, T., & Diehl, A. M. (2000) · Gastroenterology · doi:10.1053/gast.2000.19267 · Cited by 357
Francque, S., Verrijken, A., Caron, S., Prawitt, J., Paumelle, R., Derudas, B., Lefebvre, P., Taskinen, M.-R., Van Hul, W., Mertens, I., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.019 · Cited by 357
Imajo, K., Fujita, K., Yoneda, M., Nozaki, Y., Ogawa, Y., Shinohara, Y., Kato, S., Mawatari, H., Shibata, W., Kitani, H., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.05.012 · Cited by 341 · cited 2×
“In addition to leptin promoting profibrogenic responses via TGF-β signaling [83,84], obesity-induced leptin exacerbates NASH via enhancing the responsiveness to endotoxins [85], suggesting that leptin plays a key role in proinflammatory, profibrogenic processes involved in the progression of NAFLD.”
BackgroundApolipoprotein synthesis in nonalcoholic steatohepatitis
Charlton, M., Sreekumar, R., Rasmussen, D., Lindor, K., & Nair, S. K. (2002) · Hepatology · doi:10.1053/jhep.2002.32527 · Cited by 333
ER Stress Drives Lipogenesis and Steatohepatitis via Caspase-2 Activation of S1P
Kim, J. Y., Garcia-Carbonell, R., Yamachika, S., Zhao, P., Dhar, D., Loomba, R., Kaufman, R. J., Saltiel, A. R., & Karin, M. (2018) · Cell · doi:10.1016/j.cell.2018.08.020 · Cited by 333
Kim, J. K., Michael, M. D., Previs, S. F., Peroni, O. D., Mauvais-Jarvis, F., Neschen, S., Kahn, B. B., Kahn, C. R., & Shulman, G. I. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8305 · Cited by 331 · cited 1×
“In MIRKO mice, insulin-stimulated muscle glucose transport and glycogen synthesis were decreased, whereas insulin-stimulated glucose transport in the adipose tissue was increased, suggesting that selective inactivation of muscle insulin signaling resulted in redistribution of substrates from the muscle to adipose tiss…”
BackgroundSREBPs suppress IRS-2-mediated insulin signalling in the liver
Ide, T., Shimano, H., Yahagi, N., Matsuzaka, T., Nakakuki, M., Yamamoto, T., Nakagawa, Y., Takahashi, A., Suzuki, H., Sone, H., et al. (2004) · Nature Cell Biology · doi:10.1038/ncb1111 · Cited by 322
Moon, Y.-A., Liang, G., Xie, X., Frank-Kamenetsky, M., Fitzgerald, K., Koteliansky, V., Brown, M. S., Goldstein, J. L., & Horton, J. D. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2011.12.017 · Cited by 320
Huang, Y., Cohen, J. C., & Hobbs, H. H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.290114 · Cited by 314
Zhao, L., Zhang, C., Luo, X., Wang, P., Zhou, W., Zhong, S., Xie, Y., Jiang, Y., Yang, P., Tang, R., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.04.006 · Cited by 313
Matsuda, M., Korn, B. S., Hammer, R. E., Moon, Y.-A., Komuro, R., Horton, J. D., Goldstein, J. L., Brown, M. S., & Shimomura, I. (2001) · Genes & Development · doi:10.1101/gad.891301 · Cited by 303
BasuRay, S., Smagris, E., Cohen, J. C., & Hobbs, H. H. (2017) · Hepatology · doi:10.1002/hep.29273 · Cited by 302
Schwimmer, J. B., Johnson, J. S., Angeles, J. E., Behling, C., Belt, P. H., Borecki, I., Bross, C., Durelle, J., Goyal, N. P., Hamilton, G., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.06.028 · Cited by 298
Insulin stimulation of SREBP-1c processing in transgenic rat hepatocytes requires p70 S6-kinase
Owen, J. L., Zhang, Y., Bae, S.-H., Farooqi, M. S., Liang, G., Hammer, R. E., Goldstein, J. L., & Brown, M. S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213343109 · Cited by 291
Akt2 Is Required for Hepatic Lipid Accumulation in Models of Insulin Resistance
Leavens, K. F., Easton, R. M., Shulman, G. I., Previs, S. F., & Birnbaum, M. J. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.10.004 · Cited by 281
Titchenell, P. M., Quinn, W. J., Lu, M., Chu, Q., Lu, W., Li, C., Chen, H., Monks, B. R., Chen, J., Rabinowitz, J. D., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.04.022 · Cited by 281
Taniguchi, C. M., Kondo, T., Sajan, M., Luo, J., Bronson, R., Asano, T., Farese, R., Cantley, L. C., & Kahn, C. R. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.04.005 · Cited by 279
Features, Diagnosis, and Treatment of Nonalcoholic Fatty Liver Disease
Torres, D. M., Williams, C. D., & Harrison, S. A. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.03.011 · Cited by 268
Bhanji, R. A., Narayanan, P., Allen, A. M., Malhi, H., & Watt, K. D. (2017) · Hepatology · doi:10.1002/hep.29420 · Cited by 258
PNPLA3 I148M polymorphism and progressive liver disease
Dongiovanni, P. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i41.6969 · Cited by 252 · cited 1×
“Several studies have confirmed that the I148M variant predisposes to progression along the full spectrum of liver damage associated with fatty liver, from simple steatosis to steatohepatitis and progressive fibrosis, and could promote fibrogenesis in other liver diseases, including alcoholic liver diseases, viral hepa…”
BackgroundSabaté, J.-M., Jouët, P., Harnois, F., Mechler, C., Msika, S., Grossin, M., & Coffin, B. (2008) · Obesity Surgery · doi:10.1007/s11695-007-9398-2 · Cited by 251
Circulating leptin in non-alcoholic fatty liver disease: A systematic review and meta-analysis
Polyzos, S. A., Aronis, K. N., Kountouras, J., Raptis, D. D., Vasiloglou, M. F., & Mantzoros, C. S. (2016) · Diabetologia · doi:10.1007/s00125-015-3769-3 · Cited by 248 · cited 1×
“Circulating leptin levels have been reported to be higher in patients with NAFLD than in controls, and higher levels of circulating leptin have been shown with increasing severity of NAFLD [82].”
BackgroundKubota, N., Kubota, T., Itoh, S., Kumagai, H., Kozono, H., Takamoto, I., Mineyama, T., Ogata, H., Tokuyama, K., Ohsugi, M., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.05.007 · Cited by 244
Self-citationFujita, K., Nozaki, Y., Wada, K., Yoneda, M., Fujimoto, Y., Fujitake, M., Endo, H., Takahashi, H., Inamori, M., Kobayashi, N., et al. (2009) · Hepatology · doi:10.1002/hep.23094 · Cited by 244 · cited 1×
“Despite a greater degree of impairment of VLDL synthesis and secretion in cases of NASH than in those of NAFL, the hepatic TG content was found to be similar between NAFL and NASH, suggesting that impairment of VLDL synthesis might result in increased lipid oxidation and DNA oxidative damage, resulting in the progress…”
BackgroundInsulin receptor Thr1160 phosphorylation mediates lipid-induced hepatic insulin resistance
Petersen, M. C., Madiraju, A. K., Gassaway, B. M., Marcel, M., Nasiri, A. R., Butrico, G., Marcucci, M. J., Zhang, D., Abulizi, A., Zhang, X.-M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86013 · Cited by 240
Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids
Vatner, D. F., Majumdar, S. K., Kumashiro, N., Petersen, M. C., Rahimi, Y., Gattu, A. K., Bears, M., Camporez, J.-P. G., Cline, G. W., Jurczak, M. J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1423952112 · Cited by 235
Lysophospholipid Acyltransferases and Arachidonate Recycling in Human Neutrophils
Gijón, M. A., Riekhof, W. R., Zarini, S., Murphy, R. C., & Voelker, D. R. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m806194200 · Cited by 226
Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver
Honda, H., Ikejima, K., Hirose, M., Yoshikawa, M., Lang, T., Enomoto, N., Kitamura, T., Takei, Y., & Sato, N. (2002) · Hepatology · doi:10.1053/jhep.2002.33684 · Cited by 222
Nair, S. (2001) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(01)02265-1 · Cited by 212
Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia
Bauer, T. M., Schwacha, H., Steinbruckner, B., Brinkmann, F. E., Ditzen, A. K., Aponte, J. J., Pelz, K., Berger, D., Kist, M., & Blum, H. E. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05791.x · Cited by 211
Haas, J. T., Miao, J., Chanda, D., Wang, Y., Zhao, E., Haas, M. E., Hirschey, M., Vaitheesvaran, B., Farese, R. V., Kurland, I. J., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.05.002 · Cited by 210
Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth
Lichtman, S. N., Sartor, R. B., Keku, J., & Schwab, J. H. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)90833-m · Cited by 209
Rabøl, R., Petersen, K. F., Dufour, S., Flannery, C., & Shulman, G. I. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110105108 · Cited by 196
Dalamaga, M., Chou, S. H., Shields, K., Papageorgiou, P., Polyzos, S. A., & Mantzoros, C. S. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.05.010 · Cited by 190
Kapil, S., Duseja, A., Sharma, B. K., Singla, B., Chakraborti, A., Das, A., Ray, P., Dhiman, R. K., & Chawla, Y. (2016) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13058 · Cited by 173
Zhang, J., Zhao, Y., Xu, C., Hong, Y., Lu, H., Wu, J., & Chen, Y. (2014) · Scientific Reports · doi:10.1038/srep05832 · Cited by 172
A Membrane-Bound Diacylglycerol Species Induces PKCϵ-Mediated Hepatic Insulin Resistance
Lyu, K., Zhang, Y., Zhang, D., Kahn, M., ter Horst, K. W., Rodrigues, M. R. S., Gaspar, R. C., Hirabara, S. M., Luukkonen, P. K., Lee, S., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.08.001 · Cited by 170
Hepatic insulin signalling is dispensable for suppression of glucose output by insulin in vivo
Titchenell, P. M., Chu, Q., Monks, B. R., & Birnbaum, M. J. (2015) · Nature Communications · doi:10.1038/ncomms8078 · Cited by 169
Kubota, T., Kubota, N., & Kadowaki, T. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.03.004 · Cited by 169
Self-citationFlannery, C., Dufour, S., Rabøl, R., Shulman, G. I., & Petersen, K. F. (2012) · Diabetes · doi:10.2337/db12-0206 · Cited by 168
Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease
Boutari, C., Perakakis, N., & Mantzoros, C. S. (2018) · Endocrinology and Metabolism · doi:10.3803/enm.2018.33.1.33 · Cited by 167
Londos, C., Honnor, R. C., & Dhillon, G. S. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)95713-3 · Cited by 165
Congenital generalized lipodystrophy: significance of triglyceride biosynthetic pathways
Agarwal, A. K., & Garg, A. (2003) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(03)00078-x · Cited by 165
Chang, Y., Cho, Y. K., Kim, Y., Sung, E., Ahn, J., Jung, H., Yun, K. E., Shin, H., & Ryu, S. (2019) · Hepatology · doi:10.1002/hep.30170 · Cited by 162
Cantley, J. L., Yoshimura, T., Camporez, J. P. G., Zhang, D., Jornayvaz, F. R., Kumashiro, N., Guebre-Egziabher, F., Jurczak, M. J., Kahn, M., Guigni, B. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219456110 · Cited by 161
Genetic and epigenetic factors determining NAFLD risk
Jonas, W., & Schürmann, A. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101111 · Cited by 157
Brown, J. M., Betters, J. L., Lord, C., Ma, Y., Han, X., Yang, K., Alger, H. M., Melchior, J., Sawyer, J., Shah, R., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m010256 · Cited by 154
rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis
Teo, K., Abeysekera, K. W. M., Adams, L., Aigner, E., Anstee, Q. M., Banales, J. M., Banerjee, R., Basu, P., Berg, T., Bhatnagar, P., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.027 · Cited by 152
Nasr, P., Ignatova, S., Kechagias, S., & Ekstedt, M. (2018) · Hepatology Communications · doi:10.1002/hep4.1134 · Cited by 151
Sopasakis, V. R., Liu, P., Suzuki, R., Kondo, T., Winnay, J., Tran, T. T., Asano, T., Smyth, G., Sajan, M. P., Farese, R. V., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.02.002 · Cited by 148
Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease
Coulon, S., Francque, S., Colle, I. O., Verrijken, A., Blomme, B., Heindryckx, F., Munter, S. D., Prawitt, J., Caron, S., Staels, B., et al. (2012) · Cytokine · doi:10.1016/j.cyto.2012.05.001 · Cited by 148
Xu, H., Zhao, Q., Song, N., Yan, Z., Lin, R., Wu, S., Jiang, L., Hong, S., Xie, J., Zhou, H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19668-y · Cited by 148
Miyake, K., Ogawa, W., Matsumoto, M., Nakamura, T., Sakaue, H., & Kasuga, M. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15880 · Cited by 147
Pre-diabetes, insulin resistance, inflammation and CVD risk
Haffner, S. M. (2003) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(03)00122-0 · Cited by 145
Kubota, N., Kubota, T., Kajiwara, E., Iwamura, T., Kumagai, H., Watanabe, T., Inoue, M., Takamoto, I., Sasako, T., Kumagai, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms12977 · Cited by 143
Self-citationWan, M., Leavens, K. F., Saleh, D., Easton, R. M., Guertin, D. A., Peterson, T. R., Kaestner, K. H., Sabatini, D. M., & Birnbaum, M. J. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.09.001 · Cited by 138
Tanaka, Y., Shimanaka, Y., Caddeo, A., Kubo, T., Mao, Y., Kubota, T., Kubota, N., Yamauchi, T., Mancina, R. M., Baselli, G., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-320646 · Cited by 132
Self-citationLipodystrophy Due to Adipose Tissue–Specific Insulin Receptor Knockout Results in Progressive NAFLD
Softic, S., Boucher, J., Solheim, M. H., Fujisaka, S., Haering, M.-F., Homan, E. P., Winnay, J., Perez-Atayde, A. R., & Kahn, C. R. (2016) · Diabetes · doi:10.2337/db16-0213 · Cited by 129
Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis
Ghetti, F. D. F., de Oliveira, D. G., de Oliveira, J. M., Ferreira, L. E. V. V. D. C., Cesar, D. E., & Moreira, A. P. B. (2017) · European Journal of Nutrition · doi:10.1007/s00394-017-1524-x · Cited by 129
Leung, C. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i4.1189 · Cited by 129
Loss of hepatic Mboat7 leads to liver fibrosis
Thangapandi, V. R., Knittelfelder, O., Brosch, M., Patsenker, E., Vvedenskaya, O., Buch, S., Hinz, S., Hendricks, A., Nati, M., Herrmann, A., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-320853 · Cited by 125
JNK regulation of hepatic manifestations of the metabolic syndrome
Czaja, M. J. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.08.010 · Cited by 124
Liu, W., Cao, H., Cheng, Y., Chang, C., Lü, M., Jing, Y., Zhang, D., Yao, X., Duan, Z., Xia, H., et al. (2014) · Nature Communications · doi:10.1038/ncomms6684 · Cited by 119
NAFLD and Atherosclerosis: Two Sides of the Same Dysmetabolic Coin?
Stols-Gonçalves, D., Hovingh, G. K., Nieuwdorp, M., & Holleboom, A. G. (2019) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.08.008 · Cited by 118
The role of interleukin-6 in glucose homeostasis and lipid metabolism
Lehrskov, L. L., & Christensen, R. H. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00747-2 · Cited by 114 · cited 1×
“Although IL-6 exerts both pro- and anti-inflammatory activities depending on the context [79], chronic low-grade inflammation mediated by IL-6 in the adipose tissue could be related to the progression of NAFLD.”
BackgroundZhang, J., Ou, J., Bashmakov, Y., Horton, J. D., Brown, M. S., & Goldstein, J. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.071054598 · Cited by 108
Selective insulin resistance with differential expressions of IRS-1 and IRS-2 in human NAFLD livers
Honma, M., Sawada, S., Ueno, Y., Murakami, K., Yamada, T., Gao, J., Kodama, S., Izumi, T., Takahashi, K., Tsukita, S., et al. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0062-9 · Cited by 108
Chang, M., Yang, Z., & Yang, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218308 · Cited by 108
Sasso, F. C., Pafundi, P. C., Marfella, R., Calabrò, P., Piscione, F., Furbatto, F., Esposito, G., Galiero, R., Gragnano, F., Rinaldi, L., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0826-0 · Cited by 99
Hepatic Sdf2l1 controls feeding-induced ER stress and regulates metabolism
Sasako, T., Ohsugi, M., Kubota, N., Itoh, S., Okazaki, Y., Terai, A., Kubota, T., Yamashita, S., Nakatsukasa, K., Kamura, T., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08591-6 · Cited by 97
Self-citationTsai, M.-C., Liu, Y.-Y., Lin, C.-C., Wang, C.-C., Wu, Y.-J., Yong, C.-C., Chen, K.-D., Chuah, S.-K., Yao, C.-C., Huang, P.-Y., et al. (2020) · Nutrients · doi:10.3390/nu12030820 · Cited by 92
Masarone, M., Rosato, V., Aglitti, A., Bucci, T., Caruso, R., Salvatore, T., Sasso, F. C., Tripodi, M. F., & Persico, M. (2017) · PLOS ONE · doi:10.1371/journal.pone.0178473 · Cited by 90
Hirashima, Y., Tsuruzoe, K., Kodama, S., Igata, M., Toyonaga, T., Ueki, K., Kahn, C., & Araki, E. (2003) · Journal of Endocrinology · doi:10.1677/joe.0.1790253 · Cited by 89
Hepatic Insulin Resistance Is Not Pathway Selective in Humans With Nonalcoholic Fatty Liver Disease
ter Horst, K. W., Vatner, D. F., Zhang, D., Cline, G. W., Ackermans, M. T., Nederveen, A. J., Verheij, J., Demirkiran, A., van Wagensveld, B. A., Dallinga-Thie, G. M., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1644 · Cited by 88
ChREBP expression in the liver, adipose tissue and differentiated preadipocytes in human obesity
del Pozo, C. H., Vesperinas, G., Rubio, M. Á., Corripio‐Sánchez, R., García, A. J. T., Obregón, M.-J., & Calvo, R. M. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.07.016 · Cited by 77
Krause, C., Geißler, C., Tackenberg, H., Gammal, A. T. E., Wolter, S., Spranger, J., Mann, O., Lehnert, H., & Kirchner, H. (2020) · Diabetologia · doi:10.1007/s00125-020-05212-6 · Cited by 75
Shindo, N., Fujisawa, T., Sugimoto, K., Nojima, K., Fukai, A., Yoshikawa, Y., Wang, X., Yasuda, O., Ikegami, H., & Rakugi, H. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.12.033 · Cited by 72
Wijarnpreecha, K., Lou, S. M., Watthanasuntorn, K., Kröner, P. T., Cheungpasitporn, W., Lukens, F., Pungpapong, S., Keaveny, A. P., & Ungprasert, P. (2019) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001541 · Cited by 71
Tuberous Sclerosis Complex-1 Deficiency Attenuates Diet-Induced Hepatic Lipid Accumulation
Kenerson, H. L., Yeh, M. M., & Yeung, R. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018075 · Cited by 70
Haga, Y. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i46.12989 · Cited by 70
Cohen, S. E., Kokkotou, E., Biddinger, S. B., Kondo, T., Gebhardt, R., Kratzsch, J., Mantzoros, C. S., & Kahn, C. R. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704053200 · Cited by 66
Jois, T., Chen, W., Howard, V., Harvey, R., Youngs, K., Thalmann, C., Saha, P., Chan, L., Cowley, M. A., & Sleeman, M. W. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.07.006 · Cited by 60
Hepatic PTEN deficiency improves muscle insulin sensitivity and decreases adiposity in mice
Peyrou, M., Bourgoin, L., Poher, A.-L., Altirriba, J., Maeder, C., Caillon, A., Fournier, M., Montet, X., Rohner‐Jeanrenaud, F., & Foti, M. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.09.012 · Cited by 59
Cozzolino, D. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.2.713 · Cited by 58
Ablation of PI3K p110-α Prevents High-Fat Diet–Induced Liver Steatosis
Chattopadhyay, M., Selinger, E. S., Ballou, L. M., & Lin, R. Z. (2011) · Diabetes · doi:10.2337/db10-0869 · Cited by 56
Mechanistic Basis of Altered Morphine Disposition in Nonalcoholic Steatohepatitis
Dzierlenga, A. L., Clarke, J., Hargraves, T. L., Ainslie, G. R., Vanderah, T. W., Paine, M. F., & Cherrington, N. J. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.220764 · Cited by 55
Tsunekawa, S., Demozay, D., Briaud, I., McCuaig, J. F., Accili, D., Stein, R. W., & Rhodes, C. J. (2011) · Diabetes · doi:10.2337/db11-0340 · Cited by 52
Role of insulin receptor substrates in the progression of hepatocellular carcinoma
Sakurai, Y., Kubota, N., Takamoto, I., Obata, A., Iwamoto, M., Hayashi, T., Aihara, M., Kubota, T., Nishihara, H., & Kadowaki, T. (2017) · Scientific Reports · doi:10.1038/s41598-017-03299-3 · Cited by 51
Self-citationKato, K., Takeshita, Y., Misu, H., Zen, Y., Kaneko, S., & Takamura, T. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12271 · Cited by 48
Okamoto, Y., Ogawa, W., Nishizawa, A., Inoue, H., Teshigawara, K., Kinoshita, S., Matsuki, Y., Watanabe, E., Hiramatsu, R., Sakaue, H., et al. (2007) · Diabetes · doi:10.2337/db06-1322 · Cited by 41
Characteristics of Opioid Prescriptions to Veterans With Cirrhosis
Rogal, S. S., Beste, L. A., Youk, A. O., Fine, M. J., Ketterer, B., Zhang, H., Leipertz, S. L., Chartier, M., Good, C. B., Kraemer, K. L., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.10.021 · Cited by 40
Impaired Insulin Suppression of VLDL-Triglyceride Kinetics in Nonalcoholic Fatty Liver Disease
Poulsen, M. K., Nellemann, B., Stødkilde-Jørgensen, H., Pedersen, S. B., Grønbæk, H., & Nielsen, S. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3476 · Cited by 39
Enooku, K., Kondo, M., Fujiwara, N., Sasako, T., Shibahara, J., Kado, A., Okushin, K., Fujinaga, H., Tsutsumi, T., Nakagomi, R., et al. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-018-1472-0 · Cited by 35
Self-citationLing, A. V., Gearing, M. E., Semova, I., Shin, D., Clements, R. L., Lai, Z. W., & Biddinger, S. B. (2017) · Endocrinology · doi:10.1210/en.2017-00870 · Cited by 32
Moon, A. M., Watkins, S. E., Lok, A. S.-F., Firpi-Morell, R. J., Trinh, H. N., Kupec, J. T., Schoen, C., Neuschwander‐Tetri, B. A., & Barritt, A. S. (2020) · Digestive Diseases · doi:10.1159/000511074 · Cited by 25
Cited by
Current status and future trends of the global burden of MASLD
Miao, L., Targher, G., Byrne, C. D., Cao, Y.-Y., & Zheng, M.-H. (2024) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2024.02.007 · Cited by 781
Guo, X., Yin, X., Liu, Z., & Wang, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415489 · Cited by 412
Bo, T., Gao, L., Yao, Z., Shao, S., Wang, X., Proud, C. G., & Zhao, J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.04.006 · Cited by 293
Truong, X. T., & Lee, D. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0644 · Cited by 84
“Insulin receptor substrate 1 (IRS1) and IRS2 among IRS1–6 are the main adaptor proteins in the liver, activating phosphatidylinositol-3 kinase (PI3K) [9,11,15,19].”
InfluentialWasiak, J., & Gawlik-Kotelnicka, O. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114459 · Cited by 47
Metadata
- Authors
- Sakurai, Y., Kubota, N., Yamauchi, T., & Kadowaki, T.
- Affiliations
- The University of Tokyo (JP)
- National Institute of Biomedical Innovation, Health and Nutrition (JP)
- Toranomon Hospital (JP)
- Corresponding author
- Kubota, Naoto
- Kadowaki, Takashi
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-04-16
- Volume
- 22
- Issue
- 8
- Pages
- 4156
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8072900
- OpenAlex
- W3155254720
- Cited by
- 448
- References
- 195
- Citations by year
- 2026: 72 · 2025: 129 · 2024: 125 · 2023: 80 · 2022: 37 · 2021: 5
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Japan Society for the Promotion of Science (19K17977)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- non-alcoholic fatty liver disease, insulin resistance, hepatic insulin resistance, hepatic steatosis, liver fibrosis, de novo lipogenesis, gut microbiota, metabolic syndrome, obesity, type 2 diabetes, endoplasmic reticulum stress, liver inflammation, hepatocarcinogenesis
- MeSH terms
- Animals, Humans, Insulin, Signal Transduction, Metabolic Syndrome, Lipogenesis, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.